Royalty Pharma annual revenue
2018
2019
2020
2021
2022
2023
2024
2025
Royalty Pharma Revenue Growth & History (RPRX)
Royalty Pharma reported $2.38B in revenue for fiscal 2025, an increase of 5.06% from the previous fiscal year.
View full Royalty Pharma company overviewRoyalty Pharma annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.38B | $114.6M | +5.06% |
| 2024 | 2024-12-31 | $2.26B | −$91.0M | −3.86% |
| 2023 | 2023-12-31 | $2.35B | $117.3M | +5.24% |
| 2022 | 2022-12-31 | $2.24B | −$52.2M | −2.28% |
| 2021 | 2021-12-31 | $2.29B | $167.1M | +7.87% |
| 2020 | 2020-12-31 | $2.12B | $308.1M | +16.98% |
| 2019 | 2019-12-31 | $1.81B | $19.4M | +1.08% |
| 2018 | 2018-12-31 | $1.79B | — | — |
Royalty Pharma quarterly revenue
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $674.1M | $95.5M | +16.50% |
| Q1 2026 | 2026-03-31 | $630.6M | $62.3M | +10.97% |
| Q4 2025 | 2025-12-31 | $622.0M | $28.3M | +4.78% |
| Q3 2025 | 2025-09-30 | $609.3M | $44.6M | +7.90% |
| Q2 2025 | 2025-06-30 | $578.7M | $41.4M | +7.71% |
| Q1 2025 | 2025-03-31 | $568.2M | $269,000 | +0.05% |
| Q4 2024 | 2024-12-31 | $593.6M | −$2.4M | −0.41% |
| Q3 2024 | 2024-09-30 | $564.7M | $28.4M | +5.29% |
| Q2 2024 | 2024-06-30 | $537.3M | −$935,000 | −0.17% |
| Q1 2024 | 2024-03-31 | $568.0M | −$116.0M | −16.96% |
| Q4 2023 | 2023-12-31 | $596.1M | $30.3M | +5.36% |
| Q3 2023 | 2023-09-30 | $536.3M | −$37.1M | −6.48% |
| Q2 2023 | 2023-06-30 | $538.2M | $2.2M | +0.42% |
| Q1 2023 | 2023-03-31 | $684.0M | $121.9M | +21.69% |
| Q4 2022 | 2022-12-31 | $565.7M | −$10.0M | −1.73% |
| Q3 2022 | 2022-09-30 | $573.5M | −$12.3M | −2.10% |
| Q2 2022 | 2022-06-30 | $536.0M | −$19.0M | −3.43% |
| Q1 2022 | 2022-03-31 | $562.0M | −$11.0M | −1.92% |
| Q4 2021 | 2021-12-31 | $575.7M | — | — |
| Q3 2021 | 2021-09-30 | $585.8M | $47.4M | +8.80% |
| Q2 2021 | 2021-06-30 | $555.0M | $44.0M | +8.62% |
| Q1 2021 | 2021-03-31 | $573.0M | $72.1M | +14.40% |
| Q3 2020 | 2020-09-30 | $538.4M | $74.1M | +15.97% |
| Q2 2020 · Jun 30 | 2020-06-30 | $510.9M | $53.3M | +11.65% |
| Q1 2020 | 2020-03-31 | $500.9M | — | — |
| Q3 2019 | 2019-09-30 | $464.3M | — | — |
| Q2 2019 | 2019-06-30 | $457.6M | — | — |
Royalty Pharma revenue growth trends
Over the last five reported fiscal years, revenue grew from $2.12B to $2.38B, a compound annual growth rate of 2.30%. Royalty Pharma's latest reported quarter, Q2 2026, generated $674.1M in revenue, an increase of 16.50% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Royalty Pharma source filings ↗